Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A, Minowa T, Mizue Y, Sasaki K, Murata K, Tokita S, Nakatsugawa M, Iwabuchi S, Hashimoto S, Kubo T, Kanaseki T, Tsukahara T, Abe T, Shinohara N, Hirohashi Y, Torigoe T.
Yamada S, et al. Among authors: tokita s.
Cancer Immunol Immunother. 2023 Jul;72(7):2057-2065. doi: 10.1007/s00262-023-03388-5. Epub 2023 Feb 16.
Cancer Immunol Immunother. 2023.
PMID: 36795123
Free PMC article.